Evaluation of the Fluorescent Green of Indocyanine in the Detection of Sentinel Lymph Node in Endometrial Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-01

Study Completion Date

2023-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Selective lymphadenectomy Sentinel (LSS). This technique is already well established in breast cancer and melanoma and more recently in vulvar and cervical cancer.

Compared to lymphadenectomy, it has several theoretical advantages:

* this is a sensitive technique with a detection rate of\> 90% and a false negative rate of \<5%.
* the anatomopathological techniques used (immunohistochemistry with anti-cytokeratin antibodies, serial sections) are more sensitive than the standard histological analysis of lymphadenectomy, which allows an improvement in the detection of metastases (micro-metastases, isolated tumor cells). In the SENTI-ENDO study, it was possible to detect lymph node metastases in 11% of patients with low-risk endometrial cancer and in 15% of intermediate-risk patients.
* it avoids short-term and long-term operative and post-operative morbidity of lymphadenectomy.

Early studies of LSS in endometrial cancer demonstrated superior efficacy of the colorimetric method coupled with the Technetium 99m isotopic method with an overall detection rate of 78% \[95% CI: 73-84\]. The fluorescent green of indocyanine appears to give better results with an overall detection rate of 94% and a bilateral detection rate of 80%.

It seemed useful to take stock of this technique using this new dye.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pelvic Sentinel Node Detection Using Indocyanine Green Learning Curve

NCT04958278

Endometrial Cancer

UNKNOWN

Identification of Sentinel Lymph Nodes With Methylene Blue and Isotope

NCT00314405

Infiltrative Breast Cancer

COMPLETED NA

Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery

NCT02997553

Breast Carcinoma Head and Neck Cancer Melanoma (Skin) +7 more

COMPLETED PHASE3

Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer

NCT01886066

Endometrial Cancer Sentinel Lymph Node Indocyanine Green

COMPLETED NA

Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer

NCT02564276

Endometrial Neoplasms

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer of the Endometrium

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Major patient, without guardianship or curatorship.
* patient with endometrial cancer confirmed by biopsy.
* Invasive cancer stage FIGO I at intermediate risk and high risk and II according to the FIGO classification.
* need for surgical staging.
* performing an endovaginal ultrasound or a pelvic MRI in preoperative, if contraindication to MRI, performing a CT scan.
* subject affiliated to a social health insurance scheme.
* speaking and reading French.
* subject having dated and signed informed consent.

Exclusion Criteria

* pregnancy in progress.
* FIGO III and IV stage diagnosed preoperatively or intraoperatively.
* Cure or pre-surgery that may alter the uterine lymphatic drainage (conization, myomectomy).
* MRI or CT scan of suspected lymph nodes.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No